Travere Therapeutics (NASDAQ:TVTX - Get Free Report) issued its earnings results on Monday. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.78), Briefing.com reports. The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. Travere Therapeutics's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.27) earnings per share.
Travere Therapeutics Trading Up 3.1 %
Shares of NASDAQ TVTX traded up $0.20 during midday trading on Tuesday, reaching $6.75. The stock had a trading volume of 1,938,134 shares, compared to its average volume of 1,282,855. The company's 50 day moving average price is $7.04 and its 200 day moving average price is $7.61. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $19.54. The firm has a market cap of $513.74 million, a price-to-earnings ratio of -4.19 and a beta of 0.69.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on TVTX shares. Guggenheim reissued a "neutral" rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. HC Wainwright restated a "buy" rating and issued a $19.00 price target on shares of Travere Therapeutics in a research note on Tuesday. Piper Sandler boosted their target price on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a "neutral" rating in a research note on Thursday, January 18th. Wedbush reiterated an "outperform" rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.69.
Read Our Latest Report on Travere Therapeutics
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
